The deep dive
Biology, data, and the industry it built
GLP-1 made the headlines. But incretins, and the wider family of gut hormones around them, are now studied across cardiovascular disease, kidney disease, liver disease, neurology, and addiction medicine. This is the interactive dashboard and 123-year history.
Filter by outcome. Incretin receptor agonists are approved, in Phase 3, or have failed outright across seven distinct disease categories. Click a card to open the primary source.
Two drugs do opposite things to the same receptor. Both cause major weight loss. Here is the leading explanation.
GLP-1 and GIP are the two confirmed human incretins. But the surrounding gut-peptide network, GLP-2, glucagon, oxyntomodulin, amylin, PYY, is now a coordinated drug-design system.
| Hormone | Source | Physiological role | Drug(s) | Status |
|---|
From single-receptor agonists to triple agonists and oral small molecules. Click a column header to sort.
| Candidate | Company | Targets | Phase | Weight loss | Dosing |
|---|